Alglucosidase alfa
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II
Conditions
Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease, Glycogenosis 2
Trial Timeline
Jan 1, 2003 → Oct 1, 2003
NCT ID
NCT00051935About Alglucosidase alfa
Alglucosidase alfa is a phase 2 stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is completed. This product is registered under clinical trial identifier NCT00051935. Target conditions include Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04676373 | Approved | Completed |
| NCT01710813 | Pre-clinical | Completed |
| NCT01410890 | Approved | Completed |
| NCT00566878 | Pre-clinical | Completed |
| NCT01526785 | Approved | Terminated |
| NCT01288027 | Approved | Completed |
| NCT00486889 | Approved | Completed |
| NCT00483379 | Approved | Completed |
| NCT00455195 | Approved | Completed |
| NCT00074919 | Pre-clinical | Completed |
| NCT00051935 | Phase 2 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II